Evidence map›Paper›PMID 42280578›Full record

ArticlePolymers2026

mRNA Delivery by Lipoamino Fatty Acid-Peptide Polyplexes in Different Lung Cell Models and Lungs.

Sophie Thalmayr, Joschka Müller, Vivien Polewka, Irene Gialdini, Anny Nguyen, Christian Dohmen, Don C Lamb, Olivia M Merkel, Ernst Wagner

Abstract read
In one paragraph

Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sophie ThalmayrPharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.ORCID 0009-0000-6457-3965
Joschka MüllerCNATM-Cluster for Nucleic Acid Therapeutics Munich, 81377 Munich, Germany.
Vivien PolewkaCNATM-Cluster for Nucleic Acid Therapeutics Munich, 81377 Munich, Germany.
Irene GialdiniCenter for NanoScience (CeNS), Ludwig-Maximilians-Universität München, 80799 Munich, Germany.ORCID 0000-0001-8193-1840
Anny NguyenCNATM-Cluster for Nucleic Acid Therapeutics Munich, 81377 Munich, Germany.
Christian DohmenCNATM-Cluster for Nucleic Acid Therapeutics Munich, 81377 Munich, Germany.
Don C LambCenter for NanoScience (CeNS), Ludwig-Maximilians-Universität München, 80799 Munich, Germany.ORCID 0000-0002-0232-1903
Olivia M MerkelCenter for NanoScience (CeNS), Ludwig-Maximilians-Universität München, 80799 Munich, Germany.ORCID 0000-0002-4151-3916
Ernst WagnerPharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.ORCID 0000-0001-8413-0934

Funding

BMBF Cluster for Future 'CNATM - Cluster for Nucleic Acid Therapeutics Munich' 03ZU1201AABMBF Cluster for Future 'CNATM - Cluster for Nucleic Acid Therapeutics Munich' 03ZU1201AGDeutsche Forschungsgemeinschaft Project-ID 201269156 - SFB 1032, Project B03Deutsche Forschungsgemeinschaft Project-ID 201269156 - SFB 1032 Projects B04Deutsche Forschungsgemeinschaft project-ID EXC3092/1-533751719 - Germany's Excellence StrategyVolkswagen Foundation AZ-9A872
6 · The paper itself

Abstract

Local pulmonary delivery offers a non-invasive application route for mRNA therapeutics with the potential for high bioavailability at the target-site of applications such as mucosal vaccination or the treatment of lung diseases. However, efficient delivery remains challenging due to major lung-specific barriers, particularly mucus. Herein, pH-responsive, amphiphilic xenopeptides comprising lipoamino fatty acids and oligoamino acids (OAAs) connected in distinct branched U-shape or bundle topologies were evaluated as mRNA polyplexes for delivery to A549 and Calu-3 lung cells under standard submerged or air-liquid interface (ALI) transfection conditions, and upon intratracheal application in BALB/c mice. Optionally, polyplexes were coated with negatively charged hyaluronic acid (HA) or colloidally stabilized with poly(ethylene glycol) (PEG). For U-shapes, hydrophobic modification of the OAA domain boosted their efficiency. Interestingly, best-performing formulations varied across transfection conditions. While the bundle topology showed the highest potential in submerged cell culture, U-shaped carriers were more efficient under ALI conditions. Polyplex surface modification with HA or PEG did not strongly alter in vitro transfections, whereas hydrophobized U-shape core polyplexes combined with surface modification enhanced their efficiency in vivo. Thus, the cationizable core and surface properties of mRNA nanoparticles require specific balancing in various lung cell models and lung.

Indexed as

air–liquid interfacehyaluronic acidlungsmRNA deliverynanoparticlesPEGpolyplexshielding

Identifiers

PMID42280578
PMCPMC13259057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.